Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study.

IF 2.9 4区医学 Q2 DERMATOLOGY Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI:10.1080/09546634.2022.2112138

Atefeh Naeimifar, Saman Ahmad Nasrollahi, Aniseh Samadi, Zeinab Aryanian, Hamid Akbari Javar, Mohammadreza Rouini, Mansour Nassiri Kashani, Alireza Firooz

{"title":"Evaluation of tolerability and efficacy of a topical emulgel containing nanoliposomal ruxolitinib phosphate in the treatment of mild atopic dermatitis: a before-after single group pilot study.","authors":"Atefeh Naeimifar, Saman Ahmad Nasrollahi, Aniseh Samadi, Zeinab Aryanian, Hamid Akbari Javar, Mohammadreza Rouini, Mansour Nassiri Kashani, Alireza Firooz","doi":"10.1080/09546634.2022.2112138","DOIUrl":null,"url":null,"abstract":"Background: Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group phase IIA pilot study, we investigated the efficacy of topical nanoliposomal ruxolitinib phosphate (RuxoLip) emulgel in mild AD.Methods: Clinical evaluation was conducted on 10 patients with mild AD. The efficacy of the product as well as patient satisfaction was evaluated by local scoring atopic dermatitis (SCORAD) of AD. In addition, trans-epidermal water loss (TEWL), stratum corneum (SC) hydration, sebum, erythema, melanin content, and ultrasonographic parameters were measured before, and two and four weeks after treatment.Results: Four weeks of treatment reduced SCORAD, itching, and burning (p = .001, .001, and .001, respectively) and increased hydration, sebum, and epidermal density (p = .001, .018, and .037, respectively). SCORAD and other skin biophysical parameters improved within two weeks of treatment and then were in plateau for up to four weeks.Conclusions: The topical ruxolitinib emulgel has good short-term efficacy and tolerability.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3160-3164"},"PeriodicalIF":2.9000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2022.2112138","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Ruxolitinib is a JAK1/2 inhibitor, which inhibits the signal transduction of interferon-gamma, a cytokine implicated in the pathogenesis of atopic dermatitis (AD). In this before-after single group phase IIA pilot study, we investigated the efficacy of topical nanoliposomal ruxolitinib phosphate (RuxoLip) emulgel in mild AD.

Methods: Clinical evaluation was conducted on 10 patients with mild AD. The efficacy of the product as well as patient satisfaction was evaluated by local scoring atopic dermatitis (SCORAD) of AD. In addition, trans-epidermal water loss (TEWL), stratum corneum (SC) hydration, sebum, erythema, melanin content, and ultrasonographic parameters were measured before, and two and four weeks after treatment.

Results: Four weeks of treatment reduced SCORAD, itching, and burning (p = .001, .001, and .001, respectively) and increased hydration, sebum, and epidermal density (p = .001, .018, and .037, respectively). SCORAD and other skin biophysical parameters improved within two weeks of treatment and then were in plateau for up to four weeks.

Conclusions: The topical ruxolitinib emulgel has good short-term efficacy and tolerability.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评价含有纳米脂质体磷酸鲁索利替尼的局部乳凝胶治疗轻度特应性皮炎的耐受性和疗效:一项前后单组试点研究。

背景:Ruxolitinib是一种JAK1/2抑制剂，可抑制干扰素- γ的信号转导，干扰素- γ是一种与特应性皮炎(AD)发病有关的细胞因子。在这一前后单组IIA期中试研究中，我们研究了外用纳米脂质体磷酸茹索利替尼(RuxoLip)凝胶治疗轻度AD的疗效。方法:对10例轻度AD患者进行临床评价。采用AD局部评分特应性皮炎(scoad)评价产品疗效及患者满意度。此外，在治疗前、治疗后2周和4周测量经表皮失水(TEWL)、角质层(SC)水化、皮脂、红斑、黑色素含量和超声参数。结果:治疗4周后，SCORAD、瘙痒和灼烧症状明显减轻(p =。分别为0.001、0.001和0.001)，水合作用、皮脂和表皮密度增加(p = 0.001)。分别为0.001、0.018和0.037)。SCORAD和其他皮肤生物物理参数在治疗两周内得到改善，然后处于平台期长达四周。结论:外用ruxolitinib凝胶具有良好的短期疗效和耐受性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Dermatological Treatment 医学-皮肤病学

CiteScore

6.50

自引率

0.00%

发文量

145

审稿时长

6-12 weeks

期刊介绍： The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.